Media contact: Stéphanie Bardon – communication@genethon.fr – 01.69.47.12.78
December 15, 2017
A gene therapy alliance in X-linked chronic granulomatous disease with Orchard Therapeutics
Orchard Therapeutics (“Orchard”), a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies announces today a strategic alliance with Généthon, to develop gene therapy for X-linked chronic granulomatous disease (“X-CGD”)…. (read more)
September 21, 2017
Audentes Therapeutics announces dosing of first patient in ASPIRO for the treatment of X-Linked Myotubular Myopathy
July 25, 2017
Restore muscle strength in Duchenne muscular dystrophy through microdystrophin
June 21, 2017
New partnership for the treatment of Duchenne muscular disease (DMD)
Sarepta Therapeutics, a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, and Genethon, have signed a gene therapy research collaboration to jointly develop treatments for Duchenne… (read more)
April 5, 2017
New step towards the treatment of myotubular myopathy: gene therapy restores strength and prolongs lives in affected dogs
May 15, 2015
ASGCT 18th Annual Meeting 2015: Ana Buj Bello receives the Outstanding New Investigator Award
May 13, 2015
Selecta and Genethon Collaborate to Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform
May 7, 2015
Evidence of efficacy of gene therapy in rodents affected by a rare genetic liver disease, Crigler-Najjar syndrome
April 21, 2015
New gene therapy success in a rare disease of the immune system: Wiskott-Aldrich syndrome
November 10, 2014
